2201-P: Effectiveness and Safety of SGLT2i, GLP-1RA, and DPP-4i in Adults with T2D at Low-to-Moderate Cardiovascular Risk: An International Cohort Study
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2201-p ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von HANSEUL CHO und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: The comparative effectiveness and safety of SGLT2i and GLP-1RA in adults with T2D at low-to-moderate CV risk, who constitute most of this population, remain inadequately characterized. We conducted head-to-head comparisons versus DPP4i to inform treatment selection in routine clinical practice.
Methods
Using four databases from 2013-2021 (UK Clinical Practice Research Datalink; US Medicare and two commercial claims databases), we conducted three active-comparator cohort comparisons of SGLT2i, GLP-1RA, and DPP4i. Primary outcomes were modified MACE (all-cause mortality, stroke, MI), MACE (CV mortality, stroke, MI), and hospitalization for heart failure (HHF), with additional effectiveness and safety outcomes evaluated (Table). Propensity score fine-stratification weighting was used to adjust for confounding. HRs with 95% CIs were estimated.
Results
Over a mean follow-up of ~12 months, both GLP-1RA and SGLT2i were associated with a lower risk of modified MACE, HHF, all-cause mortality, CV mortality, and stroke compared with DPP4i. Compared with GLP-1RA, SGLT2i showed a lower risk of HHF, but higher risks of DKA and genital infections than both GLP-1RA and DPP4i, and a higher risk of lower-limb amputations (Table).
Conclusion
Among adults with T2D at low-to-moderate CV risk, GLP-1RA and SGLT2i were more effective than DPP4i in preventing adverse CV outcomes. We confirmed safety signals for SGLT2i. Disclosure H. Cho: None. W. Alkabbani: None. J. Ortega-Montiel: None. H. Yin: None. S. Cromer: Other - Spouse is employee of Depuy Synthes; Current; Johnson & Johnson. C. Byrne: None. B.M. Everett: Consultant; Current; Novo Nordisk. Consultant; Ended; Kowa Company, Ltd., Merck & Co., Inc. Research Support; Ended; Novo Nordisk. Other - Royalties; Current; UpToDate. Other - Associate Editor; Current; Circulation. J. Paik: None. D. Wexler: Other - Data Monitoring Committee; Ended; Novo Nordisk. Other - Data Monitoring Committee; Current; Amgen Inc. L.R. Azoulay: Consultant; Current; Roche Diagnostics. Consultant; Ended; Boehringer Ingelheim International GmbH. E. Patorno: Research Support; Current; Boehringer Ingelheim International GmbH, AstraZeneca, Bayer AG, National Institute of Diabetes and Digestive and Kidney Diseases, Patient-Centered Outcomes Research Institute. Other - Royalties; Current; UpToDate. Funding Patient Centered Outcomes Research Institute (DB-2020C2-20326)
Zitieren
APA
CHO, H., ALKABBANI, W., ORTEGA-MONTIEL, J., YIN, H., CROMER, S., BYRNE, C., EVERETT, B. M., PAIK, J., WEXLER, D., AZOULAY, L. R., & PATORNO, E. (2026). 2201-P: Effectiveness and Safety of SGLT2i, GLP-1RA, and DPP-4i in Adults with T2D at Low-to-Moderate Cardiovascular Risk: An International Cohort Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2201-p
Vancouver
CHO H, ALKABBANI W, ORTEGA-MONTIEL J, YIN H, CROMER S, BYRNE C, et al. 2201-P: Effectiveness and Safety of SGLT2i, GLP-1RA, and DPP-4i in Adults with T2D at Low-to-Moderate Cardiovascular Risk: An International Cohort Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2201-p
BibTeX
@article{CHO2026,
author = {CHO, HANSEUL and ALKABBANI, WAJD and ORTEGA-MONTIEL, JANINNE and YIN, HUI and CROMER, SARA and BYRNE, CAROLINE and EVERETT, BRENDAN M. and PAIK, JULIE and WEXLER, DEBORAH and AZOULAY, LAURENT R. and PATORNO, ELISABETTA},
title = {2201-P: Effectiveness and Safety of SGLT2i, GLP-1RA, and DPP-4i in Adults with T2D at Low-to-Moderate Cardiovascular Risk: An International Cohort Study},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2201-p}
}
EUVIMED